Effect of a rescue or recurrence dose of lasmiditan on efficacy and safety in the acute treatment of migraine: findings from the phase 3 trials (SAMURAI and SPARTAN)

Overview of attention for article published in BMC Neurology, August 2019

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (81st percentile)
Good Attention Score compared to outputs of the same age and source (73rd percentile)

Mentioned by

news: 1 news outlet

policy: 1 policy source

Readers on

mendeley: 35 Mendeley

Summary News Policy documents

So far, Altmetric has seen 1 policy document that references this research output.

Lasmiditan for the Acute Treatment of Migraine

Cited by Canadian Agency for Drugs and Technologies in Health on 13 Mar 2020

CADTH is an independent, not-for-profit organization responsible for providing health care decision-makers with objective evidence to help make informed decisions about the optimal use of health technologies.

This page shows the most recent policy documents that mention this research output.

Click here to find out how to access more activity.